Business Context and Reporting Period
This Form 8-K Current Report was filed by Insulet Corporation on October 24, 2012. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation arrangements.
- Annual Director Retainer: $35,000
- Initial Stock Option Grant: 25,000 shares (non-qualified option)
- 2012 Peer Director Grants: 4,000 restricted stock units and options for 4,000 shares
Material Changes
The material change reported is the appointment of Dr. John A. Fallon as a Class II director, effective October 24, 2012. His term is set to expire at the 2015 annual meeting of stockholders. This appointment alters the composition of the Board and initiates a new compensatory arrangement for Dr. Fallon.
Outlook, Risks, and Management Commentary
Management commentary is limited to the details of the appointment and the associated compensation policy. The filing notes that Dr. Fallon will receive standard non-employee director compensation, including an annual retainer, an initial stock option with a three-year vesting schedule (50% at one year, 25% at two years, and 25% at three years), and future annual equity grants. No specific risks, contingencies, or forward-looking guidance regarding business operations are included in this report.
Key Facts for Investor Verification
- Verify the exact closing stock price on October 24, 2012, to determine the exercise price of Dr. Fallon's 25,000-share option grant.
- Confirm the total number of outstanding shares and the potential dilution impact of the new director grants.
- Review the attached press release (Exhibit 99.1) for additional context on Dr. Fallon's qualifications and the Board's strategic rationale.
- Note that this filing contains no operational or financial results; refer to the most recent 10-Q or 10-K for financial performance.